Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 8/20 | 0.47 |
| ▸ | FLT1 | P17948 | 7/20 | 0.47 |
| ▸ | FLT4 | P35916 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26415100 | 0.83 | NPC1 (0.51) | ALOX15TSHRCASP1KDRFLT1 | |
| SCHEMBL14349376 | 0.82 | ALOX15 (0.47) | ALOX15TSHRCASP1NOTUMKDR | |
| SCHEMBL12548127 | 0.81 | NOTUM (0.51) | ALOX15TSHRCASP1NOTUMRAB9A | |
| SCHEMBL10100308 | 0.81 | NPC1 (0.45) | ALOX15TSHRCASP1NOTUMKDR | |
| SCHEMBL2225738 | 0.81 | ALOX15 (0.46) | ALOX15TSHRCASP1NOTUMKDR | |
| SCHEMBL2227609 | 0.81 | NOTUM (0.46) | ALOX15TSHRCASP1NOTUMKDR | |
| SCHEMBL3905196 | 0.81 | ALOX15 (0.53) | ALOX15TSHRCASP1NOTUMKDR | |
| SCHEMBL23805496 | 0.79 | KDM4E (0.51) | TSHRKDRFLT1FLT4RAB9A | |
| SCHEMBL21117272 | 0.79 | PTPN1 (0.45) | ALOX15TSHRCASP1NOTUMRAB9A | |
| SCHEMBL14349185 | 0.77 | PIK3CG (0.44) | ALOX15TSHRCASP1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-07-28 | — | — | US | disclosed |
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-15 | — | — | US | disclosed |
| US-9617224-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9505749-B2 | Quinazolinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150259297-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-17 | — | — | US | disclosed |
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-7932246-B2 | Histone deacetylase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-04-26 | — | — | US | disclosed |
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2010-06-17 | — | — | US | disclosed |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2009-12-03 | — | — | US | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | disclosed |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7453002-B2 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | ALOX15 1127/4885TSHR 2636/4885CASP1 147/4885 |
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | ALOX15 529/4885TSHR 2589/4885CASP1 1850/4885 |
| US-20090298924-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | HDAC1, HDAC3, HAT1 | ALOX15 1097/4885TSHR 1589/4885CASP1 1423/4885 |
| US-20150259297-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | ALOX15 1127/4885TSHR 2636/4885CASP1 147/4885 |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | ALOX15 529/4885TSHR 2589/4885CASP1 1850/4885 |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | ALOX15 2638/4885TSHR 66/4885CASP1 3534/4885 |
| US-20220235032-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | ALOX15 1775/4885TSHR 4807/4885CASP1 26/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | ALOX15 2755/4885TSHR 1357/4885CASP1 2066/4885 |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | ALOX15 1127/4885TSHR 2636/4885CASP1 147/4885 |
| US-20100152155-A1 | Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC11 | ALOX15 4118/4885TSHR 3783/4885CASP1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.